J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Biomarkers in the development of anti-angiogenic therapies for ovarian cancer.
TL;DR: The role of angiogenesis in the pathophysiology of ovarian cancer is reviewed and the development of the most promising anti-angiogenic drugs in this disease are discussed, including the first large phase III trials with bevacizumab which have demonstrated a disease-modifying role in ovarian cancer.
Journal ArticleDOI
JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer.
Ramez N. Eskander,Jonathan A. Ledermann,Michael J. Birrer,Keiichi Fujiwara,Stephanie Gaillard,Gary Richardson,Caimiao Wei,Mahadi Ali Baig,Fabian Zohren,Bradley J. Monk +9 more
TL;DR: The JAVELIN Ovarian PARP 100 trial is evaluating the efficacy of avelumab + CTX followed by aveluparib + talazoparib maintenance compared with CTX + bevacizumab followed by bevacsumab maintenance in patients with previously untreated epithelial OC.
Journal ArticleDOI
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Lia van Zuylen,J Bridgewater,Alex Sparreboom,Ferry A.L.M. Eskens,Peter de Bruijn,I. Sklenar,Andre S. T. Planting,Les Choi,Douglas Bootle,Christian Mueller,Jonathan A. Ledermann,Jaap Verweij +11 more
TL;DR: The novel molecular agent SAM486A is tolerable and safe in combination with a standard 5-FU regimen in patients with advanced colorectal cancer.
Journal ArticleDOI
High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT).
Carmelo Bengala,Valentina Guarneri,Jonathan A. Ledermann,Giovanni Rosti,Hannes Wandt,J. P. Lotz,J. H. Cure,Cinzia Orlandini,P. Ferrante,Pierfranco Conte,Taner Demirer +10 more
TL;DR: The analysis does not identify any subgroup of patients in 1st CR who can benefit from HDC; however, median survival of patient with no residual disease has not been reached, and the role of HGF after HDC deserves further investigation.
Journal ArticleDOI
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Marcia Hall,H.-M. Dehbi,Susana Banerjee,Rosemary Lord,Andrew R Clamp,Jonathan A. Ledermann,S. Nicum,R. Lilleywhite,R. Bowen,Agnieszka Michael,Amanda Feeney,R.M. Glasspool,Allan Hackshaw,G.J.S. Rustin +13 more
TL;DR: Nintedanib did not improve outcomes when added to oral cyclophosphamide, and more patients than expected remained on treatment for ≥6 months, which may reflect a higher proportion of patients with more indolent disease or the higher dose of cycloph phosphamide used.